Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, and Blood Diseases (STTR [R41/R42])

The summary for the Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, and Blood Diseases (STTR [R41/R42]) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, and Blood Diseases (STTR [R41/R42]): Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) that propose to define the factors and mechanisms controlling the differentiation of embryonic or adult stem or progenitor cells, either in vitro or in vivo. It is designed to stimulate new scientific advances in stem cell differentiation including technology research that may not be hypothesis driven. The long range goal of this program is the development of methods to direct the differentiation or development of stem cells along specific cell lineages to yield replacement cells for clinical use, whether the replacement cells are formed in vitro for delivery or formed in vivo in the tissue or organ environment. Mechanism of Support. This FOA will utilize the STTR (R41/R42) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with FOAs of identical scientific scope, PA-09-249, that encourages applications under the Small Business Innovation Research (SBIR) (R43/R44) grant mechanisms, and PA-09-248 that encourages applications under the Exploratory/Developmental (R21) grant mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.
Federal Grant Title: Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, and Blood Diseases (STTR [R41/R42])
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-09-250
Type of Funding: Grant
CFDA Numbers: 93.837
CFDA Descriptions: Heart and Vascular Diseases Research
Current Application Deadline: Sep 07, 2012
Original Application Deadline: Sep 07, 2012
Posted Date: Aug 12, 2009
Creation Date: Aug 12, 2009
Archive Date: Oct 08, 2012
Total Program Funding:
Maximum Federal Grant Award: $250,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Small businesses
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants
Chronic Kidney Disease in Children Central Biochemistry Laboratory (U24 Clinical Trial Not...
Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in...
Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in...
ARDS, Pneumonia, and Sepsis Phenotyping Consortium Clinical Centers (U01 Clinical Trial No...
The Relationship Between Hypertension and Inflammation
Community-Responsive Interventions to Reduce Cardiovascular Risk in American Indians and A...
Weight Loss in Obese Adults with Cardiovascular Risk Factors: Clinical Interventions (U01)
More Grants from the National Institutes of Health
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com